Valproic Acid News and Research

RSS

Valproic Acid is a drug used to treat epileptic seizures and bipolar disorder and to prevent migraine headaches. It is also being studied in the treatment of Kaposi sarcoma. It is a type of anticonvulsant, antimaniacal, and migraine headache prophylactic.

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Vagus nerve stimulation effective in inhibiting cortical spreading depression

A poster presentation at the International Headache Congress in Valencia, Spain reports that VNS inhibits cortical spreading depression (CSD), which is known to be the cause of migraine aura and a trigger for headache.

15 May 2015

DNMT1 gene essential to maintain breast and cancer stem cells

The gene and hormone soup that enables women to breastfeed their newborns also can be a recipe for breast cancer, particularly when the first pregnancy is after age 30.

12 May 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

UV researchers study neurobiological link between ASD and epilepsy

Researchers at the University of Veracruz (UV), in the west coast of Mexico, study the neurobiological link between the Autism Spectrum Disorder (ASD) and epilepsy, in order to understand the reason why the brain of an autistic child is 20-30 percent more susceptible to seizures that an infant without this condition.

6 Apr 2015

Death risk is higher for dementia patients who take antipsychotic drugs, new study shows

Drugs aimed at quelling the behavior problems of dementia patients may also hasten their deaths more than previously realized, a new study finds.

19 Mar 2015

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures).

20 Aug 2014

New technique expands number of functional cord blood stem cells for transplantation

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.

8 May 2014

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML).

17 Apr 2014

Study: Mood stabilizing drug may help prevent head and neck cancer

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

24 Mar 2014

Researchers create new nerve cells in brains and spinal cords of living mammals

UT Southwestern Medical Center researchers created new nerve cells in the brains and spinal cords of living mammals without the need for stem cell transplants to replenish lost cells.

27 Feb 2014

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy. It has also been shown to be effective for the treatment of mood disorders and migraine headaches.

17 Feb 2014

Johns Hopkins researchers discover epilepsy drug reduces obesity-related blood sugar levels

Johns Hopkins researchers have discovered that valproic acid, a widely prescribed drug for treating epilepsy, has the additional benefits of reducing fat accumulation in the liver and lowering blood sugar levels in the blood of obese mice.

30 Jan 2014

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Valproic acid can enhance neuronal regeneration following brachial plexus root avulsion

Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.

3 Dec 2013

Anti-epileptic drugs, bone loss and supplements

Antiepileptic drugs are medications used to prevent and control seizure disorders. These medications are also frequently used for other diagnoses other than seizures, however this current study concentrated on patients with a seizure disorder.

25 Nov 2013

Study could enhance process of reprogramming adult cells into embryonic-like stem cells

Bioengineers at the University of California, Berkeley, have shown that physical cues can replace certain chemicals when nudging mature cells back to a pluripotent stage, capable of becoming any cell type in the body.

23 Oct 2013